Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + CYT107 in Urothelial Carcinoma
NCT03513952Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2019
- Primary completion
- Sep 2023
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of efineptakin alfa in urothelial carcinoma (UC), sponsored by National Cancer Institute. Started Jun 2019; status: completed.
02
Drugs
efineptakin alfa
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03513952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03513952.